Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00493324 · ClinicalTrials.gov registry record · Phase 4

Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis

A Phase 4 study of Chronic Plaque Psoriasis, sponsored by Astellas Pharma.

Completed
Registry status
Phase 4
Development phase
43
Enrollment target
7
Study locations

NCT00493324 is a Phase 4 study of Chronic Plaque Psoriasis that has completed, run by Astellas Pharma. The registered enrollment target is 43 participants, below the 1,125-participant average among 6 other Chronic Plaque Psoriasis trials with a reported enrollment target (96% lower). The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00493324, a Phase 4 study of Chronic Plaque Psoriasis, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 4
Development phase
43 participants
Enrollment target
7
Study locations

Study Summary

A vaccine causes the immune system to produce antibodies (immune response) to specific germs to protect the patient. This study evaluates the immune response to the pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.

Conditions Studied

Chronic Plaque Psoriasis

Interventions

  • DRUG alefacept
  • DRUG polyvalent pneumococcal vaccine

Study Locations (7)

New York

  • - New York
  • - New York

Alabama

  • - Birmingham

California

  • - San Diego

Ohio

  • - Cleveland

Newfoundland and Labrador

  • - St. John's

Ontario

  • - Markham

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2007-07
Est. Completion 2008-07
Phase Phase 4

Sponsor

Astellas Pharma

165 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00493324

The ClinicalTrials.gov registry entry for NCT00493324 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,125-participant average among 6 other Chronic Plaque Psoriasis trials with a reported enrollment target (96% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which alefacept is the first listed.

NCT00493324 reports 7 study locations spanning 6 distinct geographic areas - top geographies include New York, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT00493324 about?

NCT00493324 is a clinical study titled "Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis". A vaccine causes the immune system to produce antibodies (immune response) to specific germs to protect the patient. This study evaluates the immune response to the pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.

What is the current status of trial NCT00493324?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2007-07. Estimated completion is 2008-07.

What conditions does trial NCT00493324 study?

This clinical trial studies the following conditions: Chronic Plaque Psoriasis.

What interventions are being tested in trial NCT00493324?

The interventions under investigation include: alefacept (DRUG), polyvalent pneumococcal vaccine (DRUG).

Who is sponsoring clinical trial NCT00493324?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00493324 being conducted?

This trial has 7 study locations across Alabama, California, New York, Ohio, Newfoundland and Labrador. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Plaque Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Plaque Psoriasis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.